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BACKGROUND: Epidemiological data indicate that lower urinary tract symptoms (LUTS)/BPH can be associated with metabolic
syndrome (MetS). Chronic inflammation has been proposed as a candidate mechanism at the crossroad between these two clinical
entities. Aim of study is to examine the correlation among pre-operatory LUTS/BPH severity, MetS features and inflammatory
infiltrates in prostatectomy specimens.
METHODS: A total of 271 consecutive men treated with simple prostatectomy were retrospectively selected for this study in two
tertiary referral centers for LUTS/BPH. Prostate diameters and volume were measured by transrectal ultrasound, LUTS scored by
International Prostate Symptom Score (IPSS) and obstruction by uroflowmetry. The International Diabetes Federation and American
Heart Association and the National Heart, Lung and Blood Institute was used to define MetS. The inflammatory infiltrate was
investigated combining anatomic location, grade and extent of flogosis into the overall inflammatory score (IS); the glandular
disruption (GD) was used as a further marker.
RESULTS: Eighty-six (31.7%) men were affected by MetS. Prostatic volume and anterior-posterior (AP) diameter were positively
associated to the number of MetS components. Among MetS determinants, only dyslipidaemia (increased serum triglycerides and
reduced serum high-density lipoprotein) was associated with an increased risk of having a prostatic volume460 cm3 (hazard ratio
(HR)¼ 3.268, Po0.001). A significant positive correlation between the presence of MetS and the IS was observed. MetS patients
presented lower uroflowmetric parameters as compared with those without MetS (Maximum flow rate (Qmax): 8.6 vs 10.1, P¼ 0.008
and average flow rate (Qave): 4.6 vs 5.3, P¼ 0.033, respectively), and higher obstructive urinary symptoms score (P¼ 0.064). A positive
correlation among both IS–GD and IPSS Score was also observed (adjusted r¼ 0.172, P¼ 0.008 and adjusted r¼ 0.128, P¼ 0.050).
CONCLUSIONS: MetS is associated with prostate volume, prostatic AP diameter and intraprostatic IS. The significantly positive
association between MetS and prostatic AP diameter could support the observation that MetS patients presented lower
uroflowmetric parameters. In conclusion, MetS can be regarded as a new determinant of prostate inflammation and BPH
progression.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) and BPH are highly prevalent
diseases in adult male.1 Historically, male LUTS were thought to
be merely related to benign prostatic enlargement. However,
a simplistic causal relationship linking prostatic overgrowth,
progressive urethral obstruction, urinary retention and LUTS, has
been challenged, based on the incomplete overlap of prostatic
enlargement with symptoms.2 In fact, investigations into the
relation of LUTS, prostate volume and urodynamic parameters
failed to identify a causative relationship between parameters of
BPH severity and symptoms, suggesting that other factors may
intervene in determining LUTS.3
Although age remains the best-recognized risk factor for LUTS,
LUTS may reflect other systemic derangements.4 Emerging data
indicate nowadays that a spectrum of age-related disorders, such
as metabolic syndrome (MetS), type 2 diabetes, cardiovascular
disease, hypogonadism or a combination thereof, have a
heretofore unrecognized, negative impact on LUTS.
MetS was proposed as an umbrella term to include subjects
affected by cardiovascular and metabolic risk factors, such as
visceral obesity, hypertension, hyperglycemia, low high-density
lipoprotein cholesterol (HDL-C) and hypertriglyceridemia, in the
effort to identify a diagnostic category able to predict cardiovas-
cular-metabolic complications. Several MetS components have
been closely associated with BPH, suggesting that MetS has very
heterogeneous clinical ramifications.5–9
Although the exact nature and origins of the association
between LUTS/BPH and MetS are still poorly understood,10 finding
that men with metabolic alterations show a faster-developing
BPH5 or are more likely to undergo BPH surgery8 support the
intriguing hypothesis that pathological alterations characterizing
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MetS also predispose to the development and progression of
BPH/LUTS. Chronic inflammation has been proposed as a candidate
mechanism at the crossroad between these two clinical entities.
MetS can broadly be considered a systemic inflammatory state and
a chronic inflammation-driven tissue remodeling, and overgrowth
is recognized to have a causative role in BPH/LUTS.11
The aim of the present study is to retrospectively examine the
correlation among pre-operatory LUTS/BPH severity, MetS features
and inflammatory infiltrates in prostatectomy specimens of men
with BPH.
MATERIALS AND METHODS
Study population and design
Between January 2010 and September 2011, 271 consecutive patients treated
with simple prostatectomy for BPH, with signed informed consent, were retro-
spectively selected in two tertiary referral centers for LUTS/BPH. The study did
not required any deviation of the current clinical practice and was conducted
in accordance with the principles of research involving human subjects as
expressed in the Declaration of Helsinki and with Good Clinical Practice.
Inclusion criteria were: prostatectomy for moderate to severe LUTS
because of BPH not responding to conventional medical treatment, ability
to communicate, understand and comply with study requirements.
Exclusion criteria were: history of preceding prostate surgery, previous
catheterization for acute urinary retention, chronic medication for pro-
statitis and/or urinary infection or bladder stone, known malignant disease
including prostate cancer, chronic renal failure.
Height, weight, waist circumference and blood pressure, were measured
by trained personnel using a standardized protocol. Body mass index was
calculated by dividing the weight (kg) by the square of height (m). Waist
circumference was measured midway between the lowest rib and the iliac
to the nearest 0.1 cm.
Blood samples were drawn in the morning, after an overnight fast, for
determination of blood glucose, total cholesterol, HDL-C and triglycerides,
7–30 days preoperatively.
Open transvesical prostatectomy and TURP were performed as pre-
viously reported.12,13 Surgical specimens (taken by at least three different
randomly selected sites of the adenomatous tissue) were collected with
sterile procedure and used for both conventional histological examination
and inflammatory pattern definition.
Assessment of LUTS and BPH features
LUTS were measured by the International Prostate Symptom Score (IPSS)
immediately before surgery and further evaluated and categorized as
storage (irritative) and voiding (obstructive) symptoms respectively.
All patients had digital rectal examination, uroflowmetry, abdominal
ultrasound and transrectal ultrasound of the prostate. The main diameters
of the prostate (AP: antero-posterior; CC: cranio-caudal; LL: latero-lateral)
were measured by transrectal ultrasound and the prostate volume was
calculated using the prostate ellipsoid formula (APCC LL p/6).
Maximum flow rate (Qmax) and average flow rate (Qave) were collected
preoperatively. Uroflowmetry data were analyzed only if voided volume
exceeded 150ml.
Definition of MetS
MetS was defined by the International Diabetes Federation (IDF) and
American Heart Association and the National Heart, Lung and Blood
Institute (AHA/NHLBI).14,15 The IDF and AHA/NHLBI criteria defined MetS in
the presence of three or more of the five characteristics of (1) waist
circumference4102 cm; (2) triglyceridesX150mg/dl or treatment for
hypetrygliceridemia, (3) HDL-Co40mgdl 1 or treatment for reduced
HDL-C, (4) blood pressureX130/85mmHg or current use of anti-
hypertensive medications, and (5) fasting blood glucose 4100mgdl 1
or previous diagnosis of type 2 diabetes mellitus.
All the above mentioned items of MetS were considered individually
(single parameters above vs below cut-off points), as sum of continuous
variables (one if the single parameter is positive for MetS, zero if the single
parameter is negative), and combined according to MetS (present or
absent).
Pathological characterization of prostatic inflammatory infiltrates
All surgical specimens were examined on hematoxylin and eosin-stained
sections by two independent pathologists (GN, RS), blinded of any clinical
information. Samples were investigated for the presence of an inflamma-
tory infiltrate, according to the standardized classification system of
chronic prostatitis of the National Institutes of Health (NIH).16 The resulting
parameters were defined and scored as follows: prevalent anatomical
location (stromal,1 periglandular,2 glandular3), grade (mild,1 moderate,2
severe3) and extent (focal,o10%;1 multifocal, 10–50%;2 diffuse,450%3) of
inflammatory infiltrates.
The grading methods was based on an ‘inflammatory score’ (IS),
combining all the above mentioned histological parameters, ranging from
three (mild inflammatory infiltrate) to nine (severe inflammatory infiltrate).
Moreover, the resulting destruction of the glandular epithelium, due to the
massive inflammatory infiltration, was considered as a further marker of
flogosis: ‘glandular disruption’ (GD) present or absent, see Figure 1.
Statistical analysis
Differences between more than two groups were assessed with one-way
ANOVA or Kruskal–Wallis test, whenever appropriate. For continuous
variables, correlations were assessed using Pearson’s or Spearman’s
method whenever appropriate. Stepwise multiple linear or logistic analysis
were used for multivariate analyses whenever appropriate.
All analyses were carried out with SPSS 18.0.1. (SPSS, Armonk, NY)
statistical package and a Po0.05 was considered statistically significant.
RESULTS
Overall, 271 patients treated with simple prostatectomy for BPH
were enrolled. Patient characteristics are summarized in Table 1.
One-hundred fifty-five men (57.2%) underwent open transvesical
prostatectomy, and 116 (42.8%) TURP: 204 (75.3%) were previously
treated with alpha-blockers alone, none with 5a-reductase
inhibitors alone and 67 (24.7%) with combined therapy. Thirty-
two men with MetS (31.6%) and 35 without MetS (20.6%) were
previously treated with 5a-reductase inhibitors.
Figure 1. Representative images of intraprostatic inflammation in BPH specimen. (a) Severe acute and chronic inflammatory cell infiltrate with
glandular and periglandular distribution (H&E stain, original magnification  5). (b) Epithelium disruption at higher magnification
(hematoxylin and eosin stain, original magnification  20).
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Of 271 men with BPH, 86 (31.7%) were affected by MetS. In
particular, 46 (17.0%) presented with 3/5 parameters of MetS, 34
(12.5%) 4/5 and 6 (2.2%) 5/5. The complete analysis of the
inflammatory infiltrate, including anatomic location, extent, grade,
and the determination of the GD, was available in 245/271 (90.4%)
patients; 26 men (9.6%) were excluded by the pathologists for the
lacking of an adequate sampling from different sites of the
adenomatous tissue. Mean IS, was 4.8±1.5, and GD has been
detected in 77/245 (31.4%) of cases.
Prostatic volume and AP diameter were significantly and
positively associated with the number of MetS parameters (see
Figures 2a and b), even after adjustment for age and 5a-reductase
inhibitor’s consumption (adjusted r¼ 0.151, P¼ 0.023 and adjus-
ted r¼ 0.267, Po0.0001, respectively). No correlation between
MetS and the other diameters was observed (CC: P¼ 0.198; LL:
P¼ 0.757). Patients fulfilling criteria for MetS (X3 factors) have, on
average, prostate volume 460 cm3 and AP diameter 445mm.
Moreover, men with MetS presented lower uroflowmetric para-
meters as compared with those without MetS (Qmax: 8.6 vs 10.1,
P¼ 0.008 and Qave: 4.6 vs 5.3, P¼ 0.033, respectively), and more
severe obstructive urinary symptoms, even if this difference was not
statistically significant (IPSS obstructive: 12.3 vs 11.4, P¼ 0.064).
Among MetS parameters, only increased serum triglycerides
and reduced serum HDL-C levels were associated with an
increased risk of having a prostatic volume 460 cc (see Figure 3;
hazard ratio (HR)¼ 3.268, 95% confidence interval: 1.810–5.901,
Po0.001). In addition, high serum triglycerides and low serum
HDL-C levels were significantly associated with prostate volume,
even after adjustment for age and 5a-reductase inhibitors consu-
mption (adjusted r¼ 0.273, Po0.001 and adjusted r¼  0.245,
Po0.001, respectively; see Figures 4a and b).
A significant positive correlation between the presence of MetS
and the IS was observed (age and 5a-reductase inhibitor–adjusted
HR: 1.250 (1.001–1.1561), P¼ 0.049). The association retains
significance even after introducing AP diameter as a further
covariate (HR¼ 1.295 (1.005–1.670), P¼ 0.046).
Both IS and GD were correlated with total IPSS score, even after
adjusting for age and BPH medical therapies (adjusted r¼ 0.172,
P¼ 0.008, and adjusted r¼ 0.128, P¼ 0.050, respectively, see
Figures 4a and b). In particular, a significant association between
obstructive IPSS sub-scores and both IS (adjusted r¼ 0.166,
P¼ 0.011) and GD (adjusted r¼ 0.152, P¼ 0.020) was observed,
while irritative sub-scores were not correlated either with IS and
GD. Prostate volume was not correlated with IS and GD, while AP
diameter was correlated with IS, after adjusting for age (adjusted
r¼ 0.133, P¼ 0.053). Finally, preoperative Qmax was negatively
correlated with the IS (adjusted r¼  0.212, P¼ 0.018), but not
with GD (adjusted r¼  0.044, P¼ 0.630), after the adjustment for
age and therapies for BPH.
DISCUSSION
Our study demonstrated the existence of an association among
MetS features, prostate enlargement (in particular AP diameter)
and prostate inflammation. We speculate that this pathological
network can have a relevant impact on LUTS severity in men with
histologically proven BPH.
The progressive growth of prostatic in men with BPH, with the
consequent modification of glandular profile into an oval,
rounded shape, is mainly dependent on the increase of AP
diameter.17 The AP diameter is usually the shorter one, as
compared with others diameters (CC and LL) (Aarnink et al.18
and present series). We assumed 60 cm3 and 45mm as cut-off
points for prostate volume and AP diameter, respectively, as
previously performed by other authors,19,20 even if both these
arbitrary thresholds have been not internationally recognized.
However, prostate with a volume below 60 cm3 or an AP diameter
below 45mm are conventionally considered ‘small prostate’. In
our population of BPH men treated with simple prostatectomy for
severe LUTS, both prostate volume and AP diameters were
progressively increasing as a function of MetS components.
Interestingly, the fulfilling of the diagnosic criteria for MetS






Age (years) 69±7.4 68±7.5
Weight (Kg) 81±12.0 79±9.9
Height (m) 1.73±0.1 1.73±0.1
BMI (Kgm 2) 27.4±3.5 25.4±3.6
Prostate features
AP diameter (mm) 47±11.2 42±10.7
CC diameter (mm) 51±9.6 48±9.4
LL diameter (mm) 55±8.5 52±8.9
Prostate volume (cc) 63±27.39 58±27.9
LUTS/BPH
IPSS overall 22.5±5.7 20.9±5.7
IPSS obstructive 13.7±3.8 12.3±3.0
IPSS irritative 9.0±3.0 8.6±3.0
Qmax 8.7±3.5 9.4±3.2
Qave 4.3±1.7 4.9±1.8
Abbreviations: AP, antero-posterior; BMI, body mass index; CC, cranio-
caudal; IPSS, International Prostate Symptom Score; LL, latero-lateral; LUTS,
lower urinary tract symptoms; MetS, metabolic syndrome; Qave, average
flow rate; Qmax, maximum flow rate.
Figure 2. Prostate volume (a) and AP diameter (b) as a function of the number of MetS (AHA/NHLBI criteria) components obtained in a sample
of 271 BPH subjects. Data are expressed as means±s.e.m. Red lines indicate cut-off points for both prostate volume (60 cm3) and AP diameter
(45mm), respectively. The color reproduction of this figure is available on the Prostate Cancer and Prostatic Disease journal online. AP, antero-
posterior.
Metabolic syndrome, LUTS and inflammation
M Gacci et al
102
Prostate Cancer and Prostatic Disease (2013), 100 – 105 & 2013 Macmillan Publishers Limited
(simultaneous presence of at least three components) was
associated with a pathological prostate volume and/or a AP
diameter, because resulted, on average, higher than the
aforementioned thresholds (see Figure 2). The strong and
unique association between MetS and the AP (but not CC and
LL) diameter suggests that MetS is associated not only to an
increased size, but also to a modification of its shape, which can
finally lead to a compression of the prostatic urethra, with the
consequent deterioration of the voiding function.
As showed in Figure 3, prostate volume was significantly
associated with dyslipidaemia (HDL and triglycerides), while other
MetS parameters were not. In accordance with our results,
Hammarsten et al.5,21 has previously reported that low HDL-C is
a risk factor for the development of BPH.5,21 The inconsistency of
the correlation between waist circumference and prostate volume,
reported in our study, is in agreement with other previously
reported experiences,22 while a recent clinical trial on obesity and
LUTS reported a significant and positive correlation between waist
circumference and prostate volume.23 It should be noted that the
association between prostate volume and hypertension resulted
very close to the level of MetS significance (HR¼ 1.962, 95%
confidence interval: 0.996–3.864, P¼ 0.055, see Figure 3), suggest-
ing that this component may be a potential contributor for the
growth of prostate volume, as reported by other Authors.5,21,23
A wealth of recent epidemiological and histopatological studies
have clearly indicated that prostate chronic inflammation is not
only a common finding in BPH,24,25 but also has a primary role
in triggering prostatic cells overgrowth.26,27 Potential causes for
inflammation and immune dysregulation in the prostate include
exposure to dietary factors, and metabolic variations. This notion
mainly stems from preclinical studies, which have provided a great
deal of information about an association between metabolic
diseases and LUT alterations.28,29 Our laboratory has developed,
over the last few years, an animal model of MetS by feeding adult
male rabbits a high-fat diet for twelve weeks.28–31 Interestingly,
high-fat diet induced not only the classical features of MetS (overt
dyslipidaemia, hypertension, hyperglycemia, insulin resistance and
increased visceral adiposity), but also a marked inflammation and
stromal derangement in the whole of the LUT, including the
prostate28 and bladder.29
From a pathophysiological standpoint, dyslipidemia is the best-
recognized pro-inflammatory factor among all the others MetS
features, leading to inflammation and pro-atherogenic remodeling
of the vascular wall. Hence, studies aimed at investigating the
potential pro-inflammatory effects of lipids on human prostatic
cells are needed.
Interestingly, in our study population, MetS was not only
associated with an increased prostate volume and AP diameter,
but also with a severe intraprostatic inflammation. These
observations substantiate the intriguing hypothesis that MetS
could boosts a chronic inflammation-driven prostate overgrowth.
This is particularly relevant given that MetS is an emergent
epidemic, and a potentially preventable or reversible, health
condition. Hence, if it could be definitively demonstrated that it is
causally linked to BPH/LUTS, then treating MetS would represent a
strategy not only for cardio-metabolic, but also urological
sequelae prevention.
All patients included in our study were affected by severe LUTS
(mean preoperative IPSS: 20), refractory to medical treatment, thus
requiring a surgical procedure. In particular, an IPSS score above
20 represents the worst-case scenario with regards of BPH pro-
gression.32 As showed in Figure 5, men with IPSS scores420 were
characterized by remarkable intraprostatric inflammation.
A statistically significant association between chronic inflamma-
tion and IPSS variables has been previously reported by Nickel
et al.26 in the REDUCE trial. Moreover, in the MTOPS study,
prostatic inflammation within BPH tissue resulted a relevant risk
factor for disease progression and in particular for the
development of episodes of acute urinary retention and the
needing of surgery.33 Accordingly, in our population of obstructed
men requiring a surgical procedure, only the presence of a severe
inflammatory pattern, leading to the disruption of the normal
glandular arrangement, is determinant for the worsening of LUTS.
As reported in the PLESS study, histologic features, such as chronic
inflammation, basal cell hyperplasia and transitional cell
metaplasia, were not different between men treated with 5a-
reductase inhibitors and placebo groups. In particular, the overall
incidence on chronic inflammation is very similar between those
treated with or without finasteride (16% vs 19%, respectively).34
However, 5a-reductase inhibitors can induce a regression of
prostatic glandular tissue, the specific area where the prostatic
Figure 3. Hazard ratio (HR; 95% confidence interval; adjustment for
age) for prostate volume as detected by logistic regression analysis
considering MetS components as putative predictors (AHA/NHLBI
criteria). HDL, high-density lipoprotein; MetS, metabolic syndrome.
Figure 4. Relationship between HDL (a) or triglycerides (b) level and prostate volume (ordinate) as derived from univariate Spearman’s
regression analysis. The relative adjusted r and level of significance (P) are reported in the text. HDL, high-density lipoprotein.
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inflammation is located, that can lead to a regression of prostatic
inflammation.35 In our study we adjusted the correlations between
MetS and IS for the use of 5a-reductase inhibitors to avoid this
potential bias.
Our study has several limitations. Mainly, the retrospective
design of the study; however, the number of patients was
adequate and patients were enrolled consecutively. Moreover,
prostate volume and diameters were measured only by transrectal
ultrasound, symptoms severity exclusively by assessing IPSS and
grade of obstruction just by uroflowmetry: however, all these
methods are conventionally performed in daily clinical practice for
the work up of LUTS/BPH. Theoretically, a population of untreated
men could be suitable to avoid potential confounding biases
related to previous treatments.
The strengths of the study are: the multicenter scheme and the
blinded assessment of preoperative data (MetS parameters, IPSS)
the use of standardized classification (IDF and AHA/NHLBI for MetS
and NIH for inflammation).
CONCLUSION
In conclusion, the presence of MetS is associated with a
substantial increase of prostate volume and a concomitant
modification of prostatic shape, associated with a selective
increase of anterior-posterior diameter. The significantly positive
association between MetS and prostatic AP diameter could
support the observation that MetS patients presented lower
uroflowmetric parameters. In conclusion, MetS can be relevant for
the development of a remarkable intraprostatic inflammation that
could be a predictor, or even a driver, of BPH progression.
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